Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors.
de Braud F, Machiels JH, Boggiani D, Rottey SWH, Duca M, Laruelle M, Salvagni S, Damian S, Lapeire LDF, Tiseo M, Dermine A, Ould-Kaci M, Braunger J, Rascher J, Fischer D, Hoefler J, Mariani GL, Cresta S. de Braud F, et al. Among authors: damian s. Cancers (Basel). 2020 May 31;12(6):1425. doi: 10.3390/cancers12061425. Cancers (Basel). 2020. PMID: 32486385 Free PMC article.
A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function.
Azaro A, Rodón J, Machiels JP, Rottey S, Damian S, Baird R, Garcia-Corbacho J, Mathijssen RHJ, Clot PF, Wack C, Shen L, de Jonge MJA. Azaro A, et al. Among authors: damian s. Cancer Chemother Pharmacol. 2016 Dec;78(6):1185-1197. doi: 10.1007/s00280-016-3175-7. Epub 2016 Oct 27. Cancer Chemother Pharmacol. 2016. PMID: 27796539 Free PMC article. Clinical Trial.
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG. Drilon A, et al. Among authors: damian s. Cancer Discov. 2017 Apr;7(4):400-409. doi: 10.1158/2159-8290.CD-16-1237. Epub 2017 Feb 9. Cancer Discov. 2017. PMID: 28183697 Free PMC article. Clinical Trial.
A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer.
Schöffski P, Cresta S, Mayer IA, Wildiers H, Damian S, Gendreau S, Rooney I, Morrissey KM, Spoerke JM, Ng VW, Singel SM, Winer E. Schöffski P, et al. Among authors: damian s. Breast Cancer Res. 2018 Sep 5;20(1):109. doi: 10.1186/s13058-018-1015-x. Breast Cancer Res. 2018. PMID: 30185228 Free PMC article. Clinical Trial.
Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies.
Cona MS, Lecchi M, Cresta S, Damian S, Del Vecchio M, Necchi A, Poggi MM, Raggi D, Randon G, Ratta R, Signorelli D, Vernieri C, de Braud F, Verderio P, Di Nicola M. Cona MS, et al. Among authors: damian s. Cancers (Basel). 2019 Feb 14;11(2):223. doi: 10.3390/cancers11020223. Cancers (Basel). 2019. PMID: 30769874 Free PMC article.
Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model.
Azzollini J, Vingiani A, Agnelli L, Tamborini E, Perrone F, Conca E, Capone I, Busico A, Peissel B, Rosina E, Ducceschi M, Mantiero M, Lopez S, Raspagliesi F, Niger M, Duca M, Damian S, Proto C, de Braud F, Pruneri G, Manoukian S. Azzollini J, et al. Among authors: damian s. Front Oncol. 2022 Apr 8;12:857515. doi: 10.3389/fonc.2022.857515. eCollection 2022. Front Oncol. 2022. PMID: 35463374 Free PMC article.
Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center.
Fucà G, Lecchi M, Ciniselli CM, Ottini A, Spagnoletti A, Mazzeo L, Morelli D, Frati P, Stroscia M, Ebrahem E, Sottotetti E, Galli G, D'Elia MG, Lobefaro R, Ducceschi M, Di Guardo L, Bhoori S, Provenzano S, Platania M, Niger M, Colombo E, Nichetti F, Duca M, Rivoltini L, Mortarini R, Baili P, Apolone G, de Braud F, Verderio P, Damian S. Fucà G, et al. Among authors: damian s. Ther Adv Med Oncol. 2022 Jul 27;14:17588359221108687. doi: 10.1177/17588359221108687. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35923922 Free PMC article.
40 results